In this secondary analysis of a randomized, placebo-controlled study, the administration of potassium canrenoate to patients with COVID-19-induced pneumonia resulted in an impact on the levels of specific inflammatory markers (including interleukin-6, CD3%, and TNF-α), which could potentially be linked to pulmonary fibrosis. This evidence concerns the gene IL6 and susceptibility to pneumonia measurement.